Is Pluri Inc. (PLUR) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 103.3% / 30% | 62.5% / 30% | 2.2% / 30% | 85.63% / 5% | ✗ NOT HALAL |
| DJIM | 103.3% / 33% | 62.5% / 33% | 2.2% / 33% | 85.63% / 5% | ✗ NOT HALAL |
| MSCI | 88.0% / 33% | 53.3% / 33% | 1.9% / 33% | 85.63% / 5% | ✗ NOT HALAL |
| S&P | 103.3% / 33% | 62.5% / 33% | 2.2% / 33% | 85.63% / 5% | ✗ NOT HALAL |
| FTSE | 88.0% / 33% | 53.3% / 33% | 1.9% / 50% | 85.63% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 40.6% | |
| Operating Margin | -3285.9% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -50.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$18M |
| Free Cash Flow | -$20M |
| Total Debt | $34M |
| Current Ratio | 0.4 |
| Total Assets | $39M |
Price & Trading
| Last Close | $3.21 |
| 50-Day MA | $3.41 |
| 200-Day MA | $4.08 |
| Avg Volume | 10K |
| Beta | 0.7 |
|
52-Week Range
$2.82
| |
About Pluri Inc. (PLUR)
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Pluri Inc. (PLUR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Pluri Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Pluri Inc.'s debt ratio?
Pluri Inc.'s debt ratio is 103.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 88.0%.
What are Pluri Inc.'s key financial metrics?
Pluri Inc. has a market capitalization of $33M, and revenue of $1M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.